Plain-English translation of NCT07672561 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This clinical trial is testing a new oral medication called WD-890 to see if it can help people with moderate to severe plaque psoriasis — a condition that causes thick, inflamed, scaly patches on the skin. About half of the 375 participants will receive the medication, and half will receive a placebo (a pill with no active ingredient). Researchers want to compare how well this treatment works compared to placebo and how safe it is.
Plaque psoriasis can be painful, itchy, and significantly impact quality of life. While some treatments exist, researchers are looking for new options that may work better or be safer for people living with this condition. This medication represents a potential new approach that researchers believe could help.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to take either WD-890 tablets or a placebo by mouth. You will not know which group you are in — this is called a 'blinded' study, which helps ensure fair results. You will have multiple visits to the study clinic where researchers will examine your skin, take measurements of how much it has improved, and monitor your health and safety throughout the trial.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
China